Xin Lang Cai Jing·2025-11-06 05:33Core Viewpoint - Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 587 million, marking a significant milestone for the company and enhancing its international presence [1][3]. Group 1: Company Overview - Wangshan Wangshui, established in 2013, is a comprehensive biopharmaceutical company focused on discovering, developing, and commercializing innovative small molecule drugs, particularly in the fields of neuropsychiatry, reproductive health, and viral infections [6]. - The company has developed a competitive and diversified pipeline of innovative drug products, with two products in the commercialization stage, four in clinical stages, and three in preclinical stages [3][6]. Group 2: IPO Details - The IPO of Wangshan Wangshui was highly successful, with a subscription rate of 6,238.42 times, ranking second in the healthcare sector and fourth overall among new listings on the Hong Kong Stock Exchange in 2025 [3][5]. - Citic Securities acted as the sole sponsor and played a crucial role in the IPO process, demonstrating its expertise in the biopharmaceutical sector [1][4]. Group 3: Product Development - The product "Mindewei®" received conditional approval from the National Medical Products Administration of China in January 2023 and transitioned to regular approval in January 2025 for the treatment of mild to moderate COVID-19 [6]. - The product "TPN171," marketed as "Angweida®," was approved in July 2025 for the treatment of erectile dysfunction in men [6]. Group 4: Industry Impact - Citic Securities is committed to supporting the health industry and has deepened its involvement in the medical and health sector, leveraging its comprehensive service capabilities to empower the capitalization of Chinese innovative pharmaceutical companies [4][5].